2018 Biosimilars Market Access in the EU: In-depth Knowledge of What Drives Payer and Physician Decision-making on Biosimilar Use
Comunicato Precedente
Comunicato Successivo
Biosimilars have been available in Europe for over a decade, and have offered the opportunity to vastly reduce the cost of treatment for a large number of biologic agents. In order to deliver significant savings to the healthcare structure of each individual EU member state, a careful inspection of the market access, pricing, and reimbursement mechanisms in force in each region is paramount.
An in-depth knowledge of what drives payer and physician decision-making on biosimilar use is crucial for biosimilar developers wishing to design market access strategies uniquely tailored to the specific demands in each EU member state.
This analysis summarizes key information on the process of biosimilar approval in
Europe, along with associated challenges, and provides highlights on country-specific market access, pricing, and reimbursement mechanisms which drive biosimilar uptake or prove a barrier to their entrance.
Key Topics Covered:
EXECUTIVE SUMMARY
BIOSIMILAR REGULATORY PATHWAY
INTELLECTUAL PROPERTY AND LEGAL ISSUES
NAMING AND LABELING
SUBSTITUTION AND SWITCHING
PAYER TOOLS TO DRIVE BIOSIMILAR UPTAKE
PAYER VIEWS AND TRENDS
FRANCE
GERMANY
ITALY
SPAIN
UK
BIOSIMILAR DIFFERENTIATION
METHODOLOGY
For more information about this report visit https://www.researchandmarkets.com/research/qjf9d6/2018_biosimilars?w=5
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
